ketoconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
systemic antifungal agents, miconazole derivatives	1527	65277-42-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketoconazole (+/-)-ketoconazole brizoral fungarest fungoral ketoderm ketoisdin ketozoral nizoral nizral panfungol ketoconazol R-41400	Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Molecular weight: 531.43 Formula: C26H28Cl2N4O4 CLOGP: 3.44 LIPINSKI: 1 HAC: 8 HDO: 0 TPSA: 69.06 ALOGS: -4.76 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ketoconazole
(+/-)-ketoconazole
brizoral
fungarest
fungoral
ketoderm
ketoisdin
ketozoral
nizoral
nizral
panfungol
ketoconazol
R-41400

Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.

Molecular weight: 531.43
Formula: C26H28Cl2N4O4
CLOGP: 3.44
LIPINSKI: 1
HAC: 8
HDO: 0
TPSA: 69.06
ALOGS: -4.76
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	V
0.60	g	O
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	10.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
June 12, 1981	FDA	JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	168.76	13.14	138	12255	86819	63389810
Endocrine ophthalmopathy	65.86	13.14	17	12376	654	63475975
Swelling of eyelid	64.54	13.14	24	12369	3132	63473497
Toxic shock syndrome	62.04	13.14	17	12376	825	63475804
Eyelid disorder	56.68	13.14	19	12374	1830	63474799
Nasal ulcer	56.36	13.14	20	12373	2284	63474345
Seborrhoeic dermatitis	52.90	13.14	16	12377	1105	63475524
Product use in unapproved indication	52.44	13.14	111	12282	178969	63297660
Mean cell haemoglobin increased	44.59	13.14	18	12375	2925	63473704
Dermatitis atopic	38.81	13.14	24	12369	9700	63466929
Cortisol increased	37.91	13.14	10	12383	419	63476210
Papule	36.07	13.14	19	12374	5672	63470957
Hypothalamic pituitary adrenal axis suppression	35.46	13.14	8	12385	172	63476457
Purpura senile	35.22	13.14	10	12383	553	63476076
Tarsal tunnel syndrome	35.03	13.14	10	12383	564	63476065
Dyslipidaemia	34.04	13.14	20	12373	7373	63469256
Adrenal insufficiency	33.77	13.14	28	12365	17887	63458742
Contraindicated product administered	31.60	13.14	3	12390	217645	63258984
Skin disorder	30.40	13.14	33	12360	29474	63447155
Intertrigo	29.96	13.14	9	12384	607	63476022
Eye infection	29.40	13.14	22	12371	12123	63464506
Skin exfoliation	29.27	13.14	39	12354	43063	63433566
Product dose omission issue	28.98	13.14	106	12287	234207	63242422
Vertigo positional	28.54	13.14	13	12380	2836	63473793
Pneumonia mycoplasmal	26.36	13.14	9	12384	916	63475713
Vestibular disorder	26.06	13.14	10	12383	1421	63475208
Xerosis	25.84	13.14	9	12384	973	63475656
Synovial cyst	25.48	13.14	19	12374	10414	63466215
Aspergillus test positive	25.44	13.14	7	12386	345	63476284
Dermatitis	24.91	13.14	23	12370	16935	63459694
Dry skin	23.70	13.14	41	12352	56846	63419783
Abortion spontaneous	23.69	13.14	37	12356	47158	63429471
Resorption bone increased	23.55	13.14	9	12384	1265	63475364
Feeding disorder	23.36	13.14	20	12373	13342	63463287
Impetigo	23.07	13.14	9	12384	1337	63475292
Glossodynia	22.29	13.14	4	12389	178872	63297757
Hypercholesterolaemia	22.22	13.14	24	12369	21310	63455319
Systemic lupus erythematosus	21.49	13.14	7	12386	208911	63267718
Vitamin D decreased	21.40	13.14	17	12376	10225	63466404
Pruritus	20.77	13.14	131	12262	361322	63115307
Flatulence	19.97	13.14	29	12364	34673	63441956
Exposure during pregnancy	19.74	13.14	71	12322	155476	63321153
Wound	19.60	13.14	4	12389	163259	63313370
Pelvic pain	19.21	13.14	18	12375	13501	63463128
Drug interaction	19.17	13.14	92	12301	229039	63247590
Deafness bilateral	19.06	13.14	8	12385	1434	63475195
Drug ineffective for unapproved indication	17.50	13.14	27	12366	34036	63442593
Otitis media	16.85	13.14	11	12382	4880	63471749
Skin ulcer	16.60	13.14	30	12363	43015	63433614
Lower respiratory tract infection	16.39	13.14	3	12390	132304	63344325
Drug clearance increased	16.18	13.14	4	12389	129	63476500
Blood uric acid decreased	16.04	13.14	6	12387	795	63475834
Toxicity to various agents	15.78	13.14	15	12378	247235	63229394
Psoriatic arthropathy	15.40	13.14	46	12347	91474	63385155
Hypertrophy	15.40	13.14	5	12388	436	63476193
Seborrhoeic keratosis	15.36	13.14	8	12385	2334	63474295
Discomfort	14.91	13.14	7	12386	167367	63309262
Pustule	14.68	13.14	7	12386	1692	63474937
Haematopoietic neoplasm	14.65	13.14	3	12390	40	63476589
Skin laceration	14.58	13.14	20	12373	22688	63453941
Product administration interrupted	14.55	13.14	10	12383	4826	63471803
Hepatic enzyme increased	14.47	13.14	11	12382	202317	63274312
Skin burning sensation	14.46	13.14	15	12378	12719	63463910
Infusion related reaction	14.41	13.14	16	12377	245505	63231124
Eczema	14.40	13.14	24	12369	32267	63444362
Arthrodesis	14.02	13.14	8	12385	2793	63473836
Hypokalaemia	13.69	13.14	48	12345	103756	63372873

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	53.29	13.27	63	10808	38749	34907311
Seborrhoeic dermatitis	49.51	13.27	19	10852	1689	34944371
Skin exfoliation	33.53	13.27	42	10829	27390	34918670
Pruritus	30.29	13.27	105	10766	141876	34804184
Prostatic specific antigen increased	29.21	13.27	29	10842	14651	34931409
Melanocytic naevus	28.11	13.27	14	10857	2330	34943730
Therapeutic response unexpected	26.64	13.27	23	10848	9734	34936326
Colour vision tests normal	25.53	13.27	4	10867	4	34946056
Toxicity to various agents	24.66	13.27	16	10855	200346	34745714
Anaplastic astrocytoma	24.52	13.27	6	10865	114	34945946
Product dose omission issue	24.19	13.27	87	10784	119624	34826436
Eczema	23.77	13.27	29	10842	18407	34927653
Central vision loss	22.08	13.27	4	10867	15	34946045
Alcohol intolerance	20.59	13.27	7	10864	439	34945621
Bone disorder	19.76	13.27	16	10855	6199	34939861
Seborrhoeic keratosis	19.53	13.27	9	10862	1262	34944798
Dermatitis	19.38	13.27	19	10852	9449	34936611
Product use in unapproved indication	18.54	13.27	79	10792	117420	34828640
Rash	17.61	13.27	124	10747	222628	34723432
Actinic elastosis	17.56	13.27	4	10867	55	34946005
Transient aphasia	17.31	13.27	6	10865	399	34945661
Vitamin E deficiency	17.07	13.27	3	10868	9	34946051
Scab	16.99	13.27	13	10858	4641	34941419
Rhabdomyolysis	16.81	13.27	53	10818	68110	34877950
Papule	16.08	13.27	12	10859	4127	34941933
Lentigo	16.03	13.27	6	10865	498	34945562
Blood testosterone decreased	15.53	13.27	12	10859	4345	34941715
Guttate psoriasis	15.52	13.27	5	10866	265	34945795
Skin papilloma	15.25	13.27	9	10862	2094	34943966
Herpes virus infection	15.15	13.27	10	10861	2832	34943228
Polyarteritis nodosa	14.94	13.27	5	10866	299	34945761
Drug ineffective	14.37	13.27	210	10661	456541	34489519
Metastases to bone	14.10	13.27	18	10853	11952	34934108
Hepatitis fulminant	13.77	13.27	11	10860	4179	34941881
Hormone level abnormal	13.46	13.27	5	10866	406	34945654
Dermatitis atopic	13.38	13.27	12	10859	5335	34940725

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	141.88	12.33	132	16985	89455	79637816
Endocrine ophthalmopathy	62.89	12.33	17	17100	711	79726560
Swelling of eyelid	61.33	12.33	25	17092	3786	79723485
Nasal ulcer	55.94	12.33	20	17097	2120	79725151
Toxic shock syndrome	53.82	12.33	17	17100	1232	79726039
Eyelid disorder	53.66	12.33	19	17098	1959	79725312
Cortisol increased	48.36	12.33	13	17104	532	79726739
Product dose omission issue	48.02	12.33	139	16978	247398	79479873
Seborrhoeic dermatitis	45.38	12.33	17	17100	2056	79725215
Dermatitis atopic	43.39	12.33	27	17090	10029	79717242
Toxicity to various agents	37.51	12.33	22	17095	421518	79305753
Mean cell haemoglobin increased	36.46	12.33	18	17099	4267	79723004
Impetigo	34.67	12.33	14	17103	2069	79725202
Vitamin D decreased	34.29	12.33	23	17094	9702	79717569
Adrenal insufficiency	32.20	12.33	35	17082	28452	79698819
Rhabdomyolysis	31.65	12.33	69	17048	103062	79624209
Eczema	31.06	12.33	41	17076	40777	79686494
Purpura senile	30.45	12.33	9	17108	521	79726750
Tarsal tunnel syndrome	30.35	12.33	9	17108	527	79726744
Hypothalamic pituitary adrenal axis suppression	29.77	12.33	8	17109	327	79726944
Drug interaction	28.46	12.33	169	16948	415014	79312257
Dyslipidaemia	28.38	12.33	22	17095	11611	79715660
Colour vision tests normal	27.02	12.33	4	17113	4	79727267
Eye infection	25.78	12.33	21	17096	11899	79715372
Vertigo positional	25.43	12.33	13	17104	3317	79723954
Drug abuse	24.59	12.33	3	17114	162688	79564583
Anaplastic astrocytoma	24.58	12.33	6	17111	166	79727105
Flatulence	23.81	12.33	37	17080	42687	79684584
Contraindicated product administered	23.58	12.33	3	17114	157535	79569736
Therapeutic response unexpected	23.41	12.33	25	17092	19921	79707350
Vestibular disorder	22.95	12.33	11	17106	2444	79724827
Intertrigo	22.60	12.33	8	17109	824	79726447
Synovial cyst	22.33	12.33	18	17099	10047	79717224
Central vision loss	22.31	12.33	4	17113	22	79727249
Pelvic pain	21.69	12.33	20	17097	13361	79713910
Resorption bone increased	21.45	12.33	9	17108	1466	79725805
Pneumonia mycoplasmal	21.43	12.33	9	17108	1469	79725802
Skin disorder	21.19	12.33	31	17086	33912	79693359
Hypercholesterolaemia	20.42	12.33	25	17092	23070	79704201
Dermatitis	20.36	12.33	24	17093	21297	79705974
Pruritus	19.41	12.33	148	16969	394500	79332771
Headache	18.54	12.33	218	16899	653554	79073717
Transient aphasia	18.49	12.33	6	17111	474	79726797
Deafness bilateral	18.06	12.33	9	17108	2176	79725095
Cortisol free urine decreased	17.52	12.33	3	17114	12	79727259
Feeding disorder	16.70	12.33	19	17098	16235	79711036
Vitamin E deficiency	16.37	12.33	3	17114	19	79727252
Skin laceration	16.02	12.33	25	17092	28937	79698334
Lower respiratory tract infection	16.01	12.33	4	17113	129216	79598055
Dry skin	15.96	12.33	41	17076	67954	79659317
Aspergillus test positive	15.66	12.33	6	17111	772	79726499
Infusion related reaction	15.41	12.33	16	17101	230221	79497050
Guttate psoriasis	14.65	12.33	5	17112	462	79726809
Alcohol intolerance	14.46	12.33	5	17112	480	79726791
Arthrodesis	14.44	12.33	8	17109	2399	79724872
Hepatotoxicity	14.22	12.33	33	17084	51319	79675952
Skin ulcer	14.13	12.33	34	17083	54116	79673155
Hepatitis fulminant	14.05	12.33	12	17105	7250	79720021
Drug intolerance	13.90	12.33	22	17095	264097	79463174
Polyarteritis nodosa	13.89	12.33	5	17112	540	79726731
Skin exfoliation	13.74	12.33	34	17083	55066	79672205
Wound	13.63	12.33	4	17113	116175	79611096
General physical health deterioration	13.50	12.33	24	17093	275214	79452057
Muscle spasms	13.16	12.33	73	17044	174657	79552614
Drug clearance increased	13.00	12.33	4	17113	266	79727005
Myalgia	12.96	12.33	76	17041	185565	79541706
Blood uric acid decreased	12.74	12.33	6	17111	1282	79725989
Adrenocortical insufficiency acute	12.70	12.33	8	17109	3035	79724236
Skin candida	12.69	12.33	7	17110	2080	79725191
Penile oedema	12.34	12.33	4	17113	315	79726956

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D01AC08	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	G01AF11	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives
ATC	H02CA03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CORTICOSTEROIDS FOR SYSTEMIC USE ANTIADRENAL PREPARATIONS Anticorticosteroids
ATC	J02AB02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Imidazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D065692	Cytochrome P-450 CYP3A Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190115	Cytochrome P450 3A5 Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Histoplasmosis	indication	12962009	DOID:1731
Hypercortisolism	indication	47270006
Candidiasis of skin	indication	49883006
Seborrheic dermatitis	indication	50563003	DOID:8741
Pityriasis versicolor	indication	56454009	DOID:9060
Paracoccidioidomycosis	indication	59925007	DOID:12662
Coccidioidomycosis	indication	60826002	DOID:13450
Blastomycosis	indication	69996000	DOID:12663
Disseminated candidiasis	indication	70572005
Candidiasis of mouth	indication	79740000	DOID:14262
Tinea corporis	indication	84849002
Chromoblastomycosis	indication	187079000
Pityriasis simplex	indication	200767005
Tinea cruris	indication	399029005
Paronychia	off-label use	71906005	DOID:13117
Advanced Prostatic Carcinoma	off-label use
Torsades de pointes	contraindication	31722008
Achlorhydria	contraindication	47481007
Prolonged QT interval	contraindication	111975006
Disease of liver	contraindication	235856003	DOID:409
Telangiectasia disorder	contraindication	247479008
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.84	Basic
pKa2	3.5	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Steroid 17-alpha-hydroxylase/17,20 lyase	Enzyme	P05093	CP17A_HUMAN	INHIBITOR	IC50	7.28	WOMBAT-PK	DRUG LABEL
Cytochrome P450 11B1, mitochondrial	Enzyme	P15538	C11B1_HUMAN	INHIBITOR	IC50	6.90	SCIENTIFIC LITERATURE	DRUG LABEL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	7	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	6	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.55	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	4.62	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.08	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	4.67	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.03	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.46	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	4.73	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	4.84	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.35	DRUG MATRIX
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	5.54	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	4.40	CHEMBL
Aromatase	Enzyme	P11511	CP19A_HUMAN		Ki	6.40	CHEMBL
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	Enzyme	O15528	CP27B_HUMAN		IC50	6.47	CHEMBL
Potassium voltage-gated channel subfamily A member 10	Ion channel	Q16322	KCA10_HUMAN	BLOCKER	IC50	6.30	IUPHAR
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	4.72	CHEMBL
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	5.67	DRUG MATRIX
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		app Ki	7.20	WOMBAT-PK
Indoleamine 2,3-dioxygenase 1	Enzyme	P14902	I23O1_HUMAN		IC50	4.60	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5.58	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.24	DRUG MATRIX
Cytochrome P450 3A5	Enzyme	P20815	CP3A5_HUMAN		IC50	6.92	CHEMBL
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial	Enzyme	Q07973	CP24A_HUMAN		IC50	6.51	WOMBAT-PK
Cytochrome P450 21	Enzyme	P08686	CP21A_HUMAN		IC50	5.05	CHEMBL
Sodium/nucleoside cotransporter 1	Transporter	O00337	S28A1_HUMAN		Ki	5.82	DRUG MATRIX
Cytochrome P450 11B2, mitochondrial	Enzyme	P19099	C11B2_HUMAN	INHIBITOR	IC50	7.17	SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.13	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.72	WOMBAT-PK
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR	IC50	7	WOMBAT-PK	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	5.27	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	4.90	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.21	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.01	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	4.45	CHEMBL
Gonadotropin-releasing hormone receptor	GPCR		GNRHR_RAT		Kd	9.66	CHEMBL
Cytochrome P450 11B1	Enzyme		C11B1_BOVIN		IC50	6.82	CHEMBL
Cytochrome P450 11A1	Enzyme		CP11A_RAT		IC50	5.91	CHEMBL
Cytochrome P450 24A1	Enzyme		CP24A_RAT		IC50	4.70	CHEMBL
Cytochrome P450 7A1	Enzyme		CP7A1_RAT		IC50	6.71	CHEMBL
Cytochrome P450 51	Enzyme		CP51A_RAT		Ki	7.19	CHEMBL
Bile salt export pump	Transporter		ABCBB_RAT		IC50	4.81	CHEMBL
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	Enzyme		CP27B_MOUSE		IC50	6.44	CHEMBL
Cytochrome P450 17A1	Enzyme		CP17A_RAT		IC50	6.69	CHEMBL

External reference:

ID	Source
4019271	VUID
N0000147470	NUI
D00351	KEGG_DRUG
4019271	VANDF
C0022625	UMLSCUI
CHEBI:47519	CHEBI
KTN	PDB_CHEM_ID
CHEMBL157101	ChEMBL_ID
CHEMBL295698	ChEMBL_ID
D007654	MESH_DESCRIPTOR_UI
DB01026	DRUGBANK_ID
2568	IUPHAR_LIGAND_ID
4594	INN_ID
R9400W927I	UNII
456201	PUBCHEM_CID
202692	RXNORM
2701	MMSL
31001	MMSL
4945	MMSL
d00103	MMSL
002903	NDDF
387216007	SNOMEDCT_US
40232005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3219	CREAM	20 mg	TOPICAL	ANDA	17 sections
ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0099	CREAM	20 mg	TOPICAL	ANDA	16 sections
Ketaconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7007	AEROSOL, FOAM	20 mg	TOPICAL	NDA authorized generic	26 sections
EXTINA	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8136	AEROSOL, FOAM	20 mg	TOPICAL	NDA	25 sections
Xolegel	HUMAN PRESCRIPTION DRUG LABEL	1	16110-080	GEL	20 mg	TOPICAL	NDA	27 sections
KETOCONAZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-998	TABLET	200 mg	ORAL	ANDA	22 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	16714-955	CREAM	20 mg	TOPICAL	ANDA	18 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	21695-554	CREAM	20 mg	TOPICAL	ANDA	19 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	21695-555	CREAM	20 mg	TOPICAL	ANDA	19 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	21695-556	CREAM	20 mg	TOPICAL	ANDA	19 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	21695-562	TABLET	200 mg	ORAL	ANDA	23 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	21922-025	CREAM	20 mg	TOPICAL	ANDA	15 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	33261-739	TABLET	200 mg	ORAL	ANDA	26 sections
KETOCONAZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	35573-433	TABLET	200 mg	ORAL	ANDA	15 sections
KETOCONAZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	35573-433	TABLET	200 mg	ORAL	ANDA	15 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	43063-882	TABLET	200 mg	ORAL	ANDA	26 sections
Ketodan	HUMAN PRESCRIPTION DRUG LABEL	1	43538-530	AEROSOL, FOAM	20 mg	TOPICAL	ANDA	31 sections
Ketodan	HUMAN PRESCRIPTION DRUG LABEL	1	43538-530	AEROSOL, FOAM	20 mg	TOPICAL	ANDA	31 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	45802-465	SHAMPOO, SUSPENSION	20 mg	TOPICAL	ANDA	18 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	45802-465	SHAMPOO, SUSPENSION	20 mg	TOPICAL	ANDA	18 sections
ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	45802-532	AEROSOL, FOAM	2 g	TOPICAL	ANDA	27 sections
ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	45802-532	AEROSOL, FOAM	2 g	TOPICAL	ANDA	27 sections
ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0720	CREAM	20 mg	TOPICAL	ANDA	16 sections
ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0720	CREAM	20 mg	TOPICAL	ANDA	16 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1220	SHAMPOO, SUSPENSION	20 mg	TOPICAL	ANDA	18 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1524	CREAM	20 mg	TOPICAL	ANDA	18 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1675	CREAM	20 mg	TOPICAL	ANDA	18 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1992	TABLET	200 mg	ORAL	ANDA	26 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3288	SHAMPOO, SUSPENSION	20.50 mg	TOPICAL	ANDA	17 sections
Ketoconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5265	CREAM	20 mg	TOPICAL	ANDA	17 sections